Show Search Form

Search Results

registered interest	true false
date	exactly: or between: and
answering body
answering dept id
answering dept short name
answering dept sort name
hansard heading
house id
legislature	pref label
question text
tabling member printed
uin
answer	is ministerial correction true false date of answer exactly: or between: and answer text answering member printed grouped question UIN question first answered answering member label attachment file name title
tabling member	label

Search

967474

	registered interest
	date	04/09/2018
	answering body	Department of Health and Social Care
	answering dept id	17
	answering dept short name	Health and Social Care
	answering dept sort name	Health and Social Care
	hansard heading	Prescription Drugs: Misuse
	house id	2
	legislature	25277 pref label House of Lords
	question text	To ask Her Majesty's Government what plans they have to secure funding for existing prescribed medicines withdrawal centres.
	tabling member printed	Lord Hunt of Kings Heath
	uin	HL9967
	answer	answer is ministerial correction date of answer 17/09/2018 answer text <p>The Parliamentary under Secretary of State (Steve Brine MP) commissioned Public Health England (PHE) to review the evidence for dependence on, and withdrawal from, prescribed medicines. The review was launched in January 2018 and is due to report in spring 2019 and we await its findings. It is the responsibility of local authorities to commission services, such as the provision of withdrawal centres for addiction to prescribed medicines, to meet assessed local need. The Government currently has no plans to increase the number of these centres.</p><p>The Government has no plans to introduce a separate national helpline to support people affected by prescribed drug dependence. Help and advice on prescribed drug dependence is already available from the 111 helpline or NHS Choices. People who feel that they might be dependent on either prescribed or over the counter medicines should seek help from a health professional in the first instance (such as a general practitioner or pharmacist).</p><p>PHE’s review includes prescribed benzodiazepine drug dependence but will not consider evidence further back than 10 years ago. There are no plans to establish a public inquiry into prescribed benzodiazepine drug dependence.</p> answering member printed Lord O'Shaughnessy grouped question UIN HL9968 HL9969 HL9971 question first answered 17/09/2018 14:06:06 answering member 4545 label Biography information for Lord O'Shaughnessy
	tabling member	2024 label Biography information for Lord Hunt of Kings Heath

967475

	registered interest
	date	04/09/2018
	answering body	Department of Health and Social Care
	answering dept id	17
	answering dept short name	Health and Social Care
	answering dept sort name	Health and Social Care
	hansard heading	Prescription Drugs: Misuse
	house id	2
	legislature	25277 pref label House of Lords
	question text	To ask Her Majesty's Government what plans they have, if any, to increase the number of prescribed medicines withdrawal centres to cover the whole of England.
	tabling member printed	Lord Hunt of Kings Heath
	uin	HL9968
	answer	answer is ministerial correction date of answer 17/09/2018 answer text <p>The Parliamentary under Secretary of State (Steve Brine MP) commissioned Public Health England (PHE) to review the evidence for dependence on, and withdrawal from, prescribed medicines. The review was launched in January 2018 and is due to report in spring 2019 and we await its findings. It is the responsibility of local authorities to commission services, such as the provision of withdrawal centres for addiction to prescribed medicines, to meet assessed local need. The Government currently has no plans to increase the number of these centres.</p><p>The Government has no plans to introduce a separate national helpline to support people affected by prescribed drug dependence. Help and advice on prescribed drug dependence is already available from the 111 helpline or NHS Choices. People who feel that they might be dependent on either prescribed or over the counter medicines should seek help from a health professional in the first instance (such as a general practitioner or pharmacist).</p><p>PHE’s review includes prescribed benzodiazepine drug dependence but will not consider evidence further back than 10 years ago. There are no plans to establish a public inquiry into prescribed benzodiazepine drug dependence.</p> answering member printed Lord O'Shaughnessy grouped question UIN HL9967 HL9969 HL9971 question first answered 17/09/2018 14:06:06 answering member 4545 label Biography information for Lord O'Shaughnessy
	tabling member	2024 label Biography information for Lord Hunt of Kings Heath

967476

	registered interest
	date	04/09/2018
	answering body	Department of Health and Social Care
	answering dept id	17
	answering dept short name	Health and Social Care
	answering dept sort name	Health and Social Care
	hansard heading	Prescription Drugs: Misuse
	house id	2
	legislature	25277 pref label House of Lords
	question text	To ask Her Majesty's Government whether they will ensure that in establishing a 24 hour helpline for people affected by prescribed medicines addiction they will also ensure that adequate services are in place to refer patients to.
	tabling member printed	Lord Hunt of Kings Heath
	uin	HL9969
	answer	answer is ministerial correction date of answer 17/09/2018 answer text <p>The Parliamentary under Secretary of State (Steve Brine MP) commissioned Public Health England (PHE) to review the evidence for dependence on, and withdrawal from, prescribed medicines. The review was launched in January 2018 and is due to report in spring 2019 and we await its findings. It is the responsibility of local authorities to commission services, such as the provision of withdrawal centres for addiction to prescribed medicines, to meet assessed local need. The Government currently has no plans to increase the number of these centres.</p><p>The Government has no plans to introduce a separate national helpline to support people affected by prescribed drug dependence. Help and advice on prescribed drug dependence is already available from the 111 helpline or NHS Choices. People who feel that they might be dependent on either prescribed or over the counter medicines should seek help from a health professional in the first instance (such as a general practitioner or pharmacist).</p><p>PHE’s review includes prescribed benzodiazepine drug dependence but will not consider evidence further back than 10 years ago. There are no plans to establish a public inquiry into prescribed benzodiazepine drug dependence.</p> answering member printed Lord O'Shaughnessy grouped question UIN HL9967 HL9968 HL9971 question first answered 17/09/2018 14:06:06 answering member 4545 label Biography information for Lord O'Shaughnessy
	tabling member	2024 label Biography information for Lord Hunt of Kings Heath

967478

	registered interest
	date	04/09/2018
	answering body	Department of Health and Social Care
	answering dept id	17
	answering dept short name	Health and Social Care
	answering dept sort name	Health and Social Care
	hansard heading	Benzodiazepines: Misuse
	house id	2
	legislature	25277 pref label House of Lords
	question text	To ask Her Majesty's Government whether they will establish a public inquiry into the harmful effects of prescribed benzodiazepine drug dependence over the last 50 years.
	tabling member printed	Lord Hunt of Kings Heath
	uin	HL9971
	answer	answer is ministerial correction date of answer 17/09/2018 answer text <p>The Parliamentary under Secretary of State (Steve Brine MP) commissioned Public Health England (PHE) to review the evidence for dependence on, and withdrawal from, prescribed medicines. The review was launched in January 2018 and is due to report in spring 2019 and we await its findings. It is the responsibility of local authorities to commission services, such as the provision of withdrawal centres for addiction to prescribed medicines, to meet assessed local need. The Government currently has no plans to increase the number of these centres.</p><p>The Government has no plans to introduce a separate national helpline to support people affected by prescribed drug dependence. Help and advice on prescribed drug dependence is already available from the 111 helpline or NHS Choices. People who feel that they might be dependent on either prescribed or over the counter medicines should seek help from a health professional in the first instance (such as a general practitioner or pharmacist).</p><p>PHE’s review includes prescribed benzodiazepine drug dependence but will not consider evidence further back than 10 years ago. There are no plans to establish a public inquiry into prescribed benzodiazepine drug dependence.</p> answering member printed Lord O'Shaughnessy grouped question UIN HL9967 HL9968 HL9969 question first answered 17/09/2018 14:06:06 answering member 4545 label Biography information for Lord O'Shaughnessy
	tabling member	2024 label Biography information for Lord Hunt of Kings Heath

967470

	registered interest
	date	04/09/2018
	answering body	Department of Health and Social Care
	answering dept id	17
	answering dept short name	Health and Social Care
	answering dept sort name	Health and Social Care
	hansard heading	Health Visitors
	house id	2
	legislature	25277 pref label House of Lords
	question text	To ask Her Majesty's Government what training health visitors receive to enable them to identify incipient and actual cases of ante-natal depression, post-natal depression, and other maternal mental health issues.
	tabling member printed	Baroness Hodgson of Abinger
	uin	HL9964
	answer	answer is ministerial correction date of answer 17/09/2018 answer text <p>Health visitors are part of the nursing profession and regulated by the Nursing and Midwifery Council (NMC). Health visitors are qualified and registered nurses or midwives who have undertaken an approved training programme in Specialist Community Public Health Nursing - Health Visiting.</p><p>The NMC has the general function of promoting high standards of education and coordinating all stages of education to ensure that health visitors are equipped with the knowledge, skills and attitudes essential for professional practice, including continuous professional development (CPD). The NMC set the standards of education and training for the nursing profession expected at undergraduate and postgraduate level and approve curricula set by individual higher education institutes. In so doing, they set out the knowledge, skills and behaviours that both postgraduate and undergraduate nurses must be able to demonstrate.</p><p>CPD is a term used to describe a number of different training and development activities which may be required for the purposes of professional practice in the National Health Service. The NMC requires 35 hours of CPD relevant to scope of practice in the three year period since registration was last renewed, or joining the register.</p><p>The NMC are in the process of rewriting their standards. For example, in the new pre-registration nursing standards the NMC specify that registrants must have proficiencies in identifying risk and vulnerability, in all settings and across the lifespan and would expect post-natal depression to be included in the curriculum.</p> answering member printed Lord O'Shaughnessy grouped question UIN HL9965 question first answered 17/09/2018 13:50:13 answering member 4545 label Biography information for Lord O'Shaughnessy
	tabling member	4301 label Biography information for Baroness Hodgson of Abinger

967472

	registered interest
	date	04/09/2018
	answering body	Department of Health and Social Care
	answering dept id	17
	answering dept short name	Health and Social Care
	answering dept sort name	Health and Social Care
	hansard heading	Health Visitors
	house id	2
	legislature	25277 pref label House of Lords
	question text	To ask Her Majesty's Government what continuous professional development health visitors are required to undertake to enable them to identify incipient and actual cases of ante-natal depression, post-natal depression, and other maternal mental health issues.
	tabling member printed	Baroness Hodgson of Abinger
	uin	HL9965
	answer	answer is ministerial correction date of answer 17/09/2018 answer text <p>Health visitors are part of the nursing profession and regulated by the Nursing and Midwifery Council (NMC). Health visitors are qualified and registered nurses or midwives who have undertaken an approved training programme in Specialist Community Public Health Nursing - Health Visiting.</p><p>The NMC has the general function of promoting high standards of education and coordinating all stages of education to ensure that health visitors are equipped with the knowledge, skills and attitudes essential for professional practice, including continuous professional development (CPD). The NMC set the standards of education and training for the nursing profession expected at undergraduate and postgraduate level and approve curricula set by individual higher education institutes. In so doing, they set out the knowledge, skills and behaviours that both postgraduate and undergraduate nurses must be able to demonstrate.</p><p>CPD is a term used to describe a number of different training and development activities which may be required for the purposes of professional practice in the National Health Service. The NMC requires 35 hours of CPD relevant to scope of practice in the three year period since registration was last renewed, or joining the register.</p><p>The NMC are in the process of rewriting their standards. For example, in the new pre-registration nursing standards the NMC specify that registrants must have proficiencies in identifying risk and vulnerability, in all settings and across the lifespan and would expect post-natal depression to be included in the curriculum.</p> answering member printed Lord O'Shaughnessy grouped question UIN HL9964 question first answered 17/09/2018 13:50:13 answering member 4545 label Biography information for Lord O'Shaughnessy
	tabling member	4301 label Biography information for Baroness Hodgson of Abinger

386886

	registered interest
	date	01/07/2015
	answering body	Department of Health
	answering dept id	17
	answering dept short name	Health
	answering dept sort name	Health
	hansard heading	Amyloidosis and Multiple Myeloma
	house id	2
	legislature	25277 pref label House of Lords
	question text	To ask Her Majesty’s Government whether they will place in the Library of the House any publications resulting from the phase 3 clinical trials approved for the potential treatment of systemic amyloidosis or multiple myeloma; and what is the National Institute of Health Research’s assessment of progress in these areas.
	tabling member printed	Lord Willis of Knaresborough
	uin	HL995
	answer	answer is ministerial correction date of answer 14/07/2015 answer text <p>There are four trials for systemic amyloidosis that are designated as ‘ongoing’ in the United Kingdom. These are being conducted by two commercial sponsors, Millennium Pharmaceuticals Inc and A.T. Development Switzerland Sarl (two studies), and one non-commercial sponsor, European Myeloma Network.</p><p> </p><p> </p><p> </p><p>Clinical trial sponsors are required to publish a summary of their trial results to the EU Clinical Trials Register within one year of their trial completing. At that point, these results will become publically available on the EU Clinical Trials Register</p><p> </p><p> </p><p> </p><p>The Department of Health, which funds the National Institute for Health Research (NIHR), is a member of the National Cancer Research Institute (NCRI). NCRI Clinical Studies Groups (CSGs) bring together clinicians, scientists, statisticians and lay representatives to coordinate development of a strategic portfolio of trials within their field. All CSGs interact with clinical research networks, funders (including NIHR) and researchers to develop studies aimed at improving outcomes for patients. The Haematological Oncology CSG has a Myeloma Subgroup and its 2013-14 annual report that includes an assessment of progress in these areas is attached and available on the NCRI website at:</p><p> </p><p><a href="http://csg.ncri.org.uk/wp-content/uploads/2014/11/NCRI-Haem-Onc-CSG-Annual-Report-2013-14.pdf" target="_blank">http://csg.ncri.org.uk/wp-content/uploads/2014/11/NCRI-Haem-Onc-CSG-Annual-Report-2013-14.pdf</a>.</p><p> </p><p> </p><p> </p><p>We cannot comment on commercial considerations. When the results are known, the commercial potential of these trial’s products will be a matter for the respective trial sponsors.</p><p> </p> answering member printed Lord Prior of Brampton grouped question UIN HL996 HL997 question first answered 14/07/2015 15:34:29 answering member 127 label Biography information for Lord Prior of Brampton attachment 1 file name NCRI-Haem-Onc-CSG-Annual-Report-2013-14.pdf title 2013-14 Annual Report
	tabling member	4151 label Biography information for Lord Willis of Knaresborough

386887

	registered interest
	date	01/07/2015
	answering body	Department of Health
	answering dept id	17
	answering dept short name	Health
	answering dept sort name	Health
	hansard heading	Amyloidosis
	house id	2
	legislature	25277 pref label House of Lords
	question text	To ask Her Majesty’s Government whether there are currently any trials for systemic amyloidosis in humans being conducted by the National Institute of Health Research charities or the commercial sector.
	tabling member printed	Lord Willis of Knaresborough
	uin	HL996
	answer	answer is ministerial correction date of answer 14/07/2015 answer text <p>There are four trials for systemic amyloidosis that are designated as ‘ongoing’ in the United Kingdom. These are being conducted by two commercial sponsors, Millennium Pharmaceuticals Inc and A.T. Development Switzerland Sarl (two studies), and one non-commercial sponsor, European Myeloma Network.</p><p> </p><p> </p><p> </p><p>Clinical trial sponsors are required to publish a summary of their trial results to the EU Clinical Trials Register within one year of their trial completing. At that point, these results will become publically available on the EU Clinical Trials Register</p><p> </p><p> </p><p> </p><p>The Department of Health, which funds the National Institute for Health Research (NIHR), is a member of the National Cancer Research Institute (NCRI). NCRI Clinical Studies Groups (CSGs) bring together clinicians, scientists, statisticians and lay representatives to coordinate development of a strategic portfolio of trials within their field. All CSGs interact with clinical research networks, funders (including NIHR) and researchers to develop studies aimed at improving outcomes for patients. The Haematological Oncology CSG has a Myeloma Subgroup and its 2013-14 annual report that includes an assessment of progress in these areas is attached and available on the NCRI website at:</p><p> </p><p><a href="http://csg.ncri.org.uk/wp-content/uploads/2014/11/NCRI-Haem-Onc-CSG-Annual-Report-2013-14.pdf" target="_blank">http://csg.ncri.org.uk/wp-content/uploads/2014/11/NCRI-Haem-Onc-CSG-Annual-Report-2013-14.pdf</a>.</p><p> </p><p> </p><p> </p><p>We cannot comment on commercial considerations. When the results are known, the commercial potential of these trial’s products will be a matter for the respective trial sponsors.</p><p> </p> answering member printed Lord Prior of Brampton grouped question UIN HL995 HL997 question first answered 14/07/2015 15:34:29 answering member 127 label Biography information for Lord Prior of Brampton attachment 1 file name NCRI-Haem-Onc-CSG-Annual-Report-2013-14.pdf title 2013-14 Annual Report
	tabling member	4151 label Biography information for Lord Willis of Knaresborough

386888

	registered interest
	date	01/07/2015
	answering body	Department of Health
	answering dept id	17
	answering dept short name	Health
	answering dept sort name	Health
	hansard heading	Amyloidosis
	house id	2
	legislature	25277 pref label House of Lords
	question text	To ask Her Majesty’s Government which of the four phase 2 or 3 clinical trials for systemic amyloidosis approved since 2004 are still ongoing; and whether any of the trials have produced sufficient positive outcomes to encourage commercial development.
	tabling member printed	Lord Willis of Knaresborough
	uin	HL997
	answer	answer is ministerial correction date of answer 14/07/2015 answer text <p>There are four trials for systemic amyloidosis that are designated as ‘ongoing’ in the United Kingdom. These are being conducted by two commercial sponsors, Millennium Pharmaceuticals Inc and A.T. Development Switzerland Sarl (two studies), and one non-commercial sponsor, European Myeloma Network.</p><p> </p><p> </p><p> </p><p>Clinical trial sponsors are required to publish a summary of their trial results to the EU Clinical Trials Register within one year of their trial completing. At that point, these results will become publically available on the EU Clinical Trials Register</p><p> </p><p> </p><p> </p><p>The Department of Health, which funds the National Institute for Health Research (NIHR), is a member of the National Cancer Research Institute (NCRI). NCRI Clinical Studies Groups (CSGs) bring together clinicians, scientists, statisticians and lay representatives to coordinate development of a strategic portfolio of trials within their field. All CSGs interact with clinical research networks, funders (including NIHR) and researchers to develop studies aimed at improving outcomes for patients. The Haematological Oncology CSG has a Myeloma Subgroup and its 2013-14 annual report that includes an assessment of progress in these areas is attached and available on the NCRI website at:</p><p> </p><p><a href="http://csg.ncri.org.uk/wp-content/uploads/2014/11/NCRI-Haem-Onc-CSG-Annual-Report-2013-14.pdf" target="_blank">http://csg.ncri.org.uk/wp-content/uploads/2014/11/NCRI-Haem-Onc-CSG-Annual-Report-2013-14.pdf</a>.</p><p> </p><p> </p><p> </p><p>We cannot comment on commercial considerations. When the results are known, the commercial potential of these trial’s products will be a matter for the respective trial sponsors.</p><p> </p> answering member printed Lord Prior of Brampton grouped question UIN HL995 HL996 question first answered 14/07/2015 15:34:29 answering member 127 label Biography information for Lord Prior of Brampton attachment 1 file name NCRI-Haem-Onc-CSG-Annual-Report-2013-14.pdf title 2013-14 Annual Report
	tabling member	4151 label Biography information for Lord Willis of Knaresborough

967440

	registered interest
	date	04/09/2018
	answering body	Department of Health and Social Care
	answering dept id	17
	answering dept short name	Health and Social Care
	answering dept sort name	Health and Social Care
	hansard heading	Community Nurses
	house id	2
	legislature	25277 pref label House of Lords
	question text	To ask Her Majesty's Government whether the number of district nurses in England in community service organisations, such as NHS Community Healthcare Trusts, has reduced since 2010; and, if so, what measures they are taking to address any problems caused by such a reduction.
	tabling member printed	Baroness Cox
	uin	HL9937
	answer	answer is ministerial correction date of answer 18/09/2018 answer text <p>Community health care services are a crucial part of the health and social care system that allows patients to be cared for at the right time in the right place.</p><p>NHS Digital data shows a reduction in the number of full time equivalent district nurses in England from 7,546 in September 2010 to 4,587 in May 2018. These include staff working in hospital trusts and clinical commissioning groups, but not staff working in primary care or in general practitioner surgeries, local authorities or other providers. The number of district nurses in independent healthcare providers increased by 273, from September 2010 to September 2017. As a result of changes made in 2009 to the ways in which community services are provided – i.e. from a range of different types of provider – this does not represent the full picture and there will be a number of district nurses providing National Health Service services in organisations that do not provide a return to the Electronic Staff Records.</p><p>The training of new district nurses is important in maintaining a workforce that can deliver the needs of the population in the community. Health Education England has commissioned and funded the District Nursing Specialist Practice Qualification at a steady state over the last six years. These are based upon the requirements that local providers have informed Health Education England. However, year on year these commissions are not fully taken up and therefore Health Education England is working to better understand the reasons this may be.</p><p>Health Education England is now exploring the capacity and capability required of our community workforce to best meet the future needs of the population. Health Education England is evaluating the skills and knowledge required within the wider community workforce including district nurses. This has involved extensive engagement across England to understand how best to meet to needs of the local population, as well as develop a role that has a more desirable career pathway for prospective healthcare professionals. The Government is also supporting incentives for postgraduates who go on to work in community nursing roles, including ‘golden hellos’.</p><p>Patient safety remains a key priority for the Department and in 2017 we restated our commitment to the NHS being the “safest healthcare system in the world”. The Care Quality Commission (CQC) assesses all registered providers that deliver regulated activities against the Fundamental Standards, below which the standard of care must not fall. Staffing is one of the Standards, and the CQC inspections check that sufficient numbers of suitably qualified, competent, skilled and experienced staff are deployed within service providers. To this effect we would expect providers to continue to ensure patient safety in the community.</p> answering member printed Lord O'Shaughnessy grouped question UIN HL9938 question first answered 18/09/2018 11:36:58 answering member 4545 label Biography information for Lord O'Shaughnessy
	tabling member	3364 label Biography information for Baroness Cox